查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495948

视网膜电图检查市场 – 2024 年至 2029 年预测

Electroretinogram Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

视网膜电图检查市场预计将从2022年的605,024,000美元成长到2029年的1,098,966,000美元，复合年增长率为8.90%。

视网膜电图测试是一种测量视网膜接收光线时发出的电脉衝的测试。视网膜电图是一种眼科检查，旨在发现视网膜正常功能的异常情况。眼睛后部的视网膜是眼睛中对光最敏感的细胞层。视网膜将光的讯息传送到大脑。感光细胞由视桿细胞和视锥细胞组成，帮助我们看到光线，然后将其传输到其他视网膜细胞，例如双极细胞。

人口老化更容易患青光眼和糖尿病视网膜病变等眼部疾病，对疾病早期诊断的需求不断增加，以及持续的技术进步预计将推动市场成长。眼睛是人体最脆弱的器官，因此眼科检查需要高度的精确度和准确度。这是市场成长的主要原因。此外，可支配收入的增加、对早期疾病诊断意识的提高以及政府对眼科研究和开发的资助的增加也推动了市场的成长。

监管支持和政府倡议

青光眼是损害眼睛视神经的疾病之一。当眼睛外表积聚一层液体，产生压力，损害视神经时，就会发生这种疾病。还有一种疾病称为渗出性脉络膜病变。青光眼是一种可导致视力丧失并最终失明的疾病。据世界卫生组织 (WHO) 称，青光眼被认为导致全球 450 万人失明。据估计，美国有1,200万人因青光眼失明，占失明病例的9%至12%。 60 岁以上的人比年轻人更容易因青光眼而视力丧失。然而，如果及早发现并治疗这种疾病，视力丧失是可以避免的。据认为，全球 40 岁以上人口中青光眼的年龄标准化盛行率为 3-5%。青光眼有两种类型：开放性青光眼和隅角闭锁性青光眼。最常见的青光眼类型称为开放性青光眼，它与多种疾病有关，包括撒哈拉以南非洲人后裔、高眼压、年龄较大、家族病史和高度近视等危险因子。

另一方面，年龄较大、处方笺以及东亚血统会增加隅角闭锁性青光眼的风险。青光眼研究基金会估计，目前约有 300 万美国人患有青光眼。美国国家眼科研究所预计，2030年，美国将有420万人，增幅超过58%。非裔美国人和拉丁裔社区比白人社区更容易患青光眼，前者患青光眼的可能性是后者的六到八倍。

模式视网膜电图测试（PERG）通常用作青光眼的诊断和治疗工具，并被认为对青光眼的早期检测有效。与其他常用于诊断和追踪青光眼患者的测试相比，图形视网膜电图检查 (PERG) 具有多种优点。具体来说，PERG 可以在疾病过程的早期检测到功能异常，在某些情况下比任何其他测试早八年。 PERG 测试的高灵敏度可以及早发现异常情况，从而及时预防视网膜神经节细胞 (RGC) 死亡。由于 PERG 可以促进更好的检测，由于与青光眼相关的失明病例数量不断增加以及人们对该疾病的认识不断增强，预计未来几年市场将显着增长。

固定 ERG 设备的需求增加

能够治疗大量患者并为广泛的专业领域或仅一个专业领域提供服务的大型医院是使用这些设备的理想地点。携带式EGR装置比固定式EGR装置更轻、更紧凑，使得携带式装置更容易移动和运输。然而，大多数携带式EGR 装置的功能较少，且不如固定 EGR 装置有效。它们在临时诊所或流动医院中效果最好，这些诊所或流动医院在没有永久性基础设施的地方提供医疗服务。由于这两种设备针对不同的消费者，因此它们对应的市场都很稳定并且呈现出健康的成长速度。

不断增加的研究和药物开发

目前眼科和视觉科学领域的研究倡议正在推动对先进诊断设备的需求，从而推动视网膜电图检查市场规模的扩大。 ERG 对于研究视网膜疾病和治疗的研究人员来说是一个有用的工具。例如，2022 年 ERG 对暗适应的研究将揭示基本的生理过程。例如，2022 年 ERG 对暗适应的研究将揭示基本的生理过程。可以使用锥体驱动的暮光 a 波来追踪锥体感光色素的恢復，这表明再生是速率限制的，而不是一阶的。此外，梅奥诊所目前正在进行一项研究，以评估光学相干断层扫描 (OCT) 和光学相干断层扫描血管造影术(OCTA) 对仰卧患者的成像能力。

北美地区将在预测期内快速成长

预计在预测期内，北美将占据视网膜电图检查市场的主要份额。这一份额是由多种因素造成的，包括人口老化、眼科疾病发病率增加、新兴国家核准和支出增加以及美国等已开发国家接受新产品的趋势。例如，美国国家眼科研究所预测，到 2030 年，大约 430 万美国人将患有青光眼，1,130 万美国人将患有糖尿病视网膜病变。此外，根据同一资讯来源，每年视力丧失和眼部护理的费用估计约为 1.39 亿美元。

主要市场进入

  • 2024年1月，科技公司Gentex Corp.宣布将收购视力增强科技公司eSight，以开发和製造下一代行动电子眼镜产品，以帮助视觉障碍者。
  • 2023 年 6 月，私人公司DW Healthcare Partners 宣布已完成对LKC Technologies, Inc. 的投资，LKC Technologies, Inc. 是一家电生理测试设备製造商，用于治疗青光眼和糖尿病视网膜病变等疾病。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行概述

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章视网膜电图市场：依技术分类

  • 介绍
  • 全场闪光 ERG (ffERG)
  • 模式 ERG (PERG)
  • 多焦点 ERG (mfERG)

第六章视网膜电图市场：副产品

  • 介绍
  • 手持式
  • 桌上

第七章视网膜电图市场：依应用分类

  • 介绍
  • 临床诊断
  • 研究

第八章视网膜电图检查市场：按地区

  • 介绍
  • 北美洲
  • 南美洲
  • 欧洲
  • 中东/非洲
  • 亚太地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 有竞争力的仪表板

第十章 公司简介

  • LKC Technologies
  • Eye Patient
  • ICR
  • WellFirst Health
  • Neurosoft
  • Roland Consult
  • Aetna
  • USF Health
  • Medico Electrodes
简介目录
Product Code: KSI061616012

The electroretinogram market is expected to grow at a CAGR of 8.90% from US$605.024 million in 2022 to US$1,098.966 million in 2029.

The term electroretinography refers to the study of the electrical impulses that the retina emits when exposed to light. To find any abnormalities in the retinas normal functioning an electroretinogram is one kind of eye that is conducted. The retina which is found at the back of the eye is the layer of cells in the eye that is most sensitive to light. The retina sends electrical messages to the brain bearing light data. Photoreceptors composed of rods and cones help us see lights before conveying it to other retinal cells like bipolar cells.

The geriatric population which is more likely to develop eye disorders like glaucoma and diabetic retinopathy as well as the growing demand for early disease diagnosis and ongoing technological advancements are anticipated to fuel market growth. Because the eyes are the most delicate organs in the body ophthalmic exam procedures require a high degree of accuracy and precision. The markets growth is primarily being driven by this. Furthermore, the market is growing due to rising levels of disposable income growing awareness of early disease diagnosis and increased government funding for ophthalmological R&D.

The imposition of regulatory support and government initiatives

One kind of illness that harms the optic nerve in the eye is glaucoma. This condition develops when a layer of fluid accumulates on the outer surface of the eye creating pressure that damages the optic nerves. Exudative choroidopathy is another name for it. One condition that can lead to visual loss and eventually blindness is glaucoma. According to the World Health Organization glaucoma is thought to be the cause of blindness in 4. 5 million people worldwide. It is estimated that glaucoma causes blindness in 120000 Americans accounting for 9-12% of all cases of blindness. Individuals over 60 are more likely than younger people to experience vision loss due to glaucoma. If the ailment is identified and treated early on however it is possible to avoid having one's vision compromised. Age-standardized prevalence estimates for glaucoma in people 40 years of age and older worldwide are thought to be between 3 and 5%. Two main subtypes of glaucoma can be distinguished: open-angle glaucoma and closed-angle glaucoma. The most common type of glaucoma is known as open-angle glaucoma which can be recognized by several risk factors such as being of African descent from sub-Saharan Africa having an elevated intraocular pressure being older having a positive family history and having high myopia.

By contrast having a strong prescription getting older and being of East Asian ethnicity increases the risk of developing closed-angle glaucoma. It is estimated by the Glaucoma Research Foundation that approximately 3 million Americans currently suffer from glaucoma. The National Eye Institute has provided projections indicating that by 2030 there could be up to 4 point 2 million people in the country-a rise of more than 58 percent. African American and Latino communities are also more likely to experience glaucoma than the Caucasian community the former are six to eight times more likely to be affected than the latter.

Pattern electroretinography or PERG is a commonly used diagnostic and therapeutic tool for glaucoma that is considered effective in identifying the disease early. Compared to other tests that are frequently used to diagnose and track glaucoma patients the Pattern Electroretinogram (PERG) offers a few advantages. Specifically, functional abnormalities can be found with PERG very early in the course of the disease in some cases this is possibly up to eight years earlier than with any of our other tests. Due to their sensitivity, PERG tests allow for the early detection of abnormalities and consequently the timely prevention of retinal ganglion cell (RGC) death. Since PERG can facilitate better detection it is expected that the market will experience significant growth in the coming years due to the rise in glaucoma-related blindness cases and increased awareness of the disease.

Increased demand for fixed ERG machines

Large hospitals with the ability to treat large numbers of patients and offer a wide range of specialities or just one are the ideal places for these devices to be used. Because the portable EGR machines are lighter and more compact than the fixed EGR machines the portable machines are easier to move and transport. However, the vast majority of portable devices are less feature-rich and less effective than their stationary counterparts. These work best in makeshift clinics and mobile hospitals that offer healthcare in places without permanent infrastructure. Since these two devices serve different kinds of consumers their corresponding markets are both stable and experiencing healthy rates of growth.

Rising research and drug development

Current ophthalmology and vision science research initiatives fuel the demand for sophisticated diagnostic instruments which in turn propels the size of the electroretinogram market. For researchers looking into retinal conditions and treatments, ERG is a useful tool. For instance ERG studies of dark adaptation in 2022 shed light on basic physiological processes. One can track cone photopigment recovery using the cone-driven dim-flash a-wave which shows that regeneration is rate-limited as opposed to first order. Additionally, the Mayo Clinic is now conducting studies to assess the imaging capabilities of optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) in supine patients.

North America is witnessing exponential growth during the forecast period

Over the course of the forecast period North America is anticipated to hold a sizable share of the electroretinogram market. This share can be attributed to several factors including an ageing population an increase in the incidence of eye problems a rise in approvals and RandD spending and a tendency in developed countries like the US to embrace novel products. By 2030 for example the National Eye Institute projects that approximately 4 Point 3 million Americans will suffer from glaucoma and 11 Point 3 million will have diabetic retinopathy. Furthermore, according to the same source, the annual cost of vision loss and eye care is estimated to be around $139 million.

Market key launches

  • In January 2024, Technology company Gentex Corp. announced, that it would acquire eSight, a provider of vision enhancement technologies, in order to create and produce the upcoming generation of mobile electronic eyewear, which will aid those who are visually impaired.
  • In June 2023, the healthcare-focused private equity firm DW Healthcare Partners announced that it had completed its investment in LKC Technologies, Inc., which makes electrophysiology testing devices that help with the diagnosis and treatment of conditions affecting the retina and optic nerve, including glaucoma and diabetic retinopathy.

Segmentation:

By Technology

  • Full-Field Flash ERG (ffERG)
  • Pattern ERG (PERG)
  • Multifocal ERG (mfERG)

By Product

  • Handheld
  • Tabletop

By Application

  • Clinical Diagnostic
  • Research

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. ELECTRORETINOGRAM MARKET, BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Full-Field Flash ERG (ffERG)
    • 5.2.1. Market Trends and Opportunities
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Pattern ERG (PERG)
    • 5.3.1. Market Trends and Opportunities
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Multifocal ERG (mfERG)
    • 5.4.1. Market Trends and Opportunities
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness

6. ELECTRORETINOGRAM MARKET, BY PRODUCT

  • 6.1. Introduction
  • 6.2. Handheld
    • 6.2.1. Market Trends and Opportunities
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Tabletop
    • 6.3.1. Market Trends and Opportunities
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness

7. ELECTRORETINOGRAM MARKET, BY APPLICATION

  • 7.1. Introduction
  • 7.2. Clinical Diagnostics
    • 7.2.1. Market Trends and Opportunities
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Research
    • 7.3.1. Market Trends and Opportunities
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness

8. ELECTRORETINOGRAM MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Technology
    • 8.2.2. By Product
    • 8.2.3. By Application
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1.Market Trends and Opportunities
        • 8.2.4.1.2.Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1.Market Trends and Opportunities
        • 8.2.4.2.2.Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1.Market Trends and Opportunities
        • 8.2.4.3.2.Growth Prospects
  • 8.3. South America
    • 8.3.1. By Technology
    • 8.3.2. By Product
    • 8.3.3. By Application
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1.Market Trends and Opportunities
        • 8.3.4.1.2.Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1.Market Trends and Opportunities
        • 8.3.4.2.2.Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1.Market Trends and Opportunities
        • 8.3.4.3.2.Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Technology
    • 8.4.2. By Product
    • 8.4.3. By Application
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1.Market Trends and Opportunities
        • 8.4.4.1.2.Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1.Market Trends and Opportunities
        • 8.4.4.2.2.Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1.Market Trends and Opportunities
        • 8.4.4.3.2.Growth Prospects
      • 8.4.4.4. Spain
        • 8.4.4.4.1.Market Trends and Opportunities
        • 8.4.4.4.2.Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1.Market Trends and Opportunities
        • 8.4.4.5.2.Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Technology
    • 8.5.2. By Product
    • 8.5.3. By Application
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1.Market Trends and Opportunities
        • 8.5.4.1.2.Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1.Market Trends and Opportunities
        • 8.5.4.2.2.Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1.Market Trends and Opportunities
        • 8.5.4.3.2.Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1.Market Trends and Opportunities
        • 8.5.4.4.2.Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Technology
    • 8.6.2. By Product
    • 8.6.3. By Application
    • 8.6.4. By Country
      • 8.6.4.1. Japan
        • 8.6.4.1.1.Market Trends and Opportunities
        • 8.6.4.1.2.Growth Prospects
      • 8.6.4.2. China
        • 8.6.4.2.1.Market Trends and Opportunities
        • 8.6.4.2.2.Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1.Market Trends and Opportunities
        • 8.6.4.3.2.Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1.Market Trends and Opportunities
        • 8.6.4.4.2.Growth Prospects
      • 8.6.4.5. Indonesia
        • 8.6.4.5.1.Market Trends and Opportunities
        • 8.6.4.5.2.Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1.Market Trends and Opportunities
        • 8.6.4.6.2.Growth Prospects
      • 8.6.4.7. Others
        • 8.6.4.7.1.Market Trends and Opportunities
        • 8.6.4.7.2.Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. LKC Technologies
  • 10.2. Eye Patient
  • 10.3. ICR
  • 10.4. WellFirst Health
  • 10.5. Neurosoft
  • 10.6. Roland Consult
  • 10.7. Aetna
  • 10.8. USF Health
  • 10.9. Medico Electrodes